Revenue Performance - For the six months ended September 30, 2025, the total revenue reached RMB 358.1 million, representing an 8.7% year-over-year increase[6]. - Revenue from the big data platform and solutions segment was RMB 153.2 million, up 14.6% compared to RMB 133.7 million in the same period last year[6]. - The health management platform and solutions segment saw a significant growth of 30.3%, with revenue increasing to RMB 66.7 million from RMB 51.2 million[6]. - Revenue for the reporting period reached RMB 138.3 million, a decrease of 4.4% year-on-year[20]. - Revenue increased by 8.7% from RMB 329.4 million for the six months ended September 30, 2024, to RMB 358.1 million for the six months ended September 30, 2025, driven by growth in the big data platform and health management solutions segments[32]. - Revenue from the big data platform and solutions segment rose by 14.6% from RMB 133.7 million to RMB 153.2 million, benefiting from expanded business opportunities due to policy support[32]. - Revenue from the health management platform and solutions segment surged by 30.3% from RMB 51.1 million to RMB 66.6 million, primarily due to changes in the product mix[32]. - Customer contract revenue for the six months ended September 30, 2025, was RMB 358,105 thousand, an increase of 8.3% compared to RMB 329,448 thousand for the same period in 2024[68]. Profitability and Loss - Gross profit for the period was RMB 134.0 million, reflecting a 14.2% increase from RMB 117.4 million in the previous year[6]. - Gross profit increased from RMB 117.4 million to RMB 134.0 million, with gross margin improving from 35.6% to 37.4%[34]. - Operating loss narrowed to RMB 15.7 million, a 71.0% improvement from a loss of RMB 54.3 million in the same period last year[6]. - Period loss reduced by 72.0% from RMB 56.4 million to RMB 15.8 million[41]. - Net loss for the period was RMB 15,760 thousand, a substantial reduction from RMB 56,362 thousand in the previous year[68]. - The company reported a basic and diluted loss per share of RMB 0.01 for the six months ended September 30, 2025, compared to RMB 0.04 in the same period of 2024[69]. Cash Flow and Financial Management - The net cash outflow from operating activities decreased by 56.0% year-over-year, indicating improved cash management[8]. - Cash and cash equivalents decreased from RMB 3,309.1 million to RMB 2,099.3 million as of September 30, 2025[42]. - Other income for the six months was RMB 80,916 thousand, slightly down from RMB 82,937 thousand in 2024[68]. - Total operating expenses, including cost of sales, sales and marketing expenses, administrative expenses, and R&D expenses, amounted to RMB 442,731,000 for the six months ended September 30, 2025, slightly up from RMB 435,455,000 in 2024[84]. User Engagement and Market Reach - The active user base on the health management platform exceeded 22 million, with over 615,000 participants in the "Shenzhen Hui Min Bao" insurance program[10]. - The "Shenzhen Huiminbao" program reached over 6.15 million participants, a historical high, with cumulative claims exceeding 390,000[24]. - Active users on the health management platform exceeded 22 million as of September 30, 2025[27]. Research and Development - The company has focused on breakthroughs in AI model development for the medical vertical, investing in a medical large language model with 70 billion parameters, trained on over 500 billion high-quality tokens[12]. - The AI-driven patient recruitment agent based on medical record understanding has significantly improved the efficiency of clinical trial recommendations and data utilization[14]. - The company has developed a lightweight application model that closely matches the performance of larger parameter models, reducing hardware computational requirements[12]. - The company has established a solid partnership network with key medical institutions and research organizations, enhancing its "AI + Medical Insurance" capabilities[21]. Awards and Recognition - The company has been recognized with industry awards, including first prize in the medical health track at the "Data Element X" competition and the best paper award at the CHIP 2025 conference[13]. Corporate Governance and Future Plans - The company has complied with the corporate governance code as per the Hong Kong Stock Exchange listing rules during the reporting period[55]. - The board of directors does not recommend the distribution of an interim dividend for the six months ended September 30, 2025[67]. - The company has no major investments or capital asset plans for the future as of September 30, 2025[46].
医渡科技(02158) - 2026 - 中期业绩